Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)

NCT02140463 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02140463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02140463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
February 28, 2014
Completion date
October 29, 2019
Enrollment
229 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genitourinary cancer, metastatic gastrointestinal cancer